Novo’s Weight Loss Drugs Removed from FDA Shortage List
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...
Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback